Document Detail


The effect of recombinant alpha-interferon on natural killer cell activity and clinical course in patients with myelodysplastic syndrome.
MedLine Citation:
PMID:  1830225     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Thirteen patients with myelodysplastic syndrome (MDS) were included in this study and consented to treatment with recombinant alpha-interferon (a-IFN). These patients were subclassified: six as RAEB, one as RAEB-T and six as CMML. T-cell subsets and natural killer cells were identified in the peripheral blood with the use of monoclonal antibodies and natural killer cell activity (NKa) was assayed before, during and after a-INF treatment. The treatment schedule consisted of 2.0 MU/m2 sc t.i.w. continuously for the three months. Prior to treatment, NKa was found decreased in 11 of 13 patients as compared to that of normal individuals. Following a-IFN administration, a rise of NKa was observed in eight of the eleven patients. In those who responded, a-IFN was continued for 1 to 21 months. Alpha-IFN treatment was myelosuppressive for most of the patients, but transient increase of the number of neutrophils and platelets was observed in 3 and of the reticulocytes in one patient. Disease progression was recorded in 9/13 patients (69%) at a median time of 17.3 months. The median overall survival was 30.5 months (range 7.5 to 65+ months). No evidence of a relationship was found between the rise in Nka and the limited clinical improvement observed. Two NKa responders under continuous a-IFN treatment are in stable clinical condition for 36+ and 65+ months. The study provides only limited evidence that a-IFN may improve the clinical course of patients with MDS.
Authors:
X Yataganas; G Eliopoulos; S Koulocheri; N Viniou; E Plata; P Panagiotidis; G Vayopoulos; J Meletis; P Fessas
Related Documents :
23609045 - Safety and efficacy of low molecular weight dextran (dextran 40) in head and neck free ...
21844815 - A randomized comparison study of aquacel ag and glucan ii as donor site dressings with ...
9614595 - Use of bupropion with sris and venlafaxine.
20945995 - The impact of previous or concomitant ifn therapy on deferiprone-induced agranulocytosi...
9128775 - Follow-up results 20 years after surgical treatment of habitual ventral shoulder luxati...
14767305 - The impact of open radical retropubic prostatectomy on continence and lower urinary tra...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of hematology     Volume:  62     ISSN:  0939-5555     ISO Abbreviation:  Ann. Hematol.     Publication Date:  1991 Jun 
Date Detail:
Created Date:  1991-08-27     Completed Date:  1991-08-27     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9107334     Medline TA:  Ann Hematol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  225-9     Citation Subset:  IM    
Affiliation:
First Department of Internal Medicine, University of Athens Medical School, Laiko Hospital, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antigens, CD3
Antigens, CD4 / analysis
Antigens, CD8
Antigens, Differentiation, T-Lymphocyte / analysis
Female
Humans
Interferon Type I / pharmacology*
Killer Cells, Natural / drug effects,  physiology*
Leukemia / etiology
Male
Middle Aged
Myelodysplastic Syndromes / drug therapy*
Receptors, Antigen, T-Cell / analysis
Recombinant Proteins / pharmacology
Chemical
Reg. No./Substance:
0/Antigens, CD3; 0/Antigens, CD4; 0/Antigens, CD8; 0/Antigens, Differentiation, T-Lymphocyte; 0/Interferon Type I; 0/Receptors, Antigen, T-Cell; 0/Recombinant Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  K+-dependent enzyme activity of H+-ATPase in the E. coli membrane
Next Document:  Contrast medium clearance as a measure of kidney function in patients with renal artery stenoses